Global Nonalcoholic Steatohepatitis Therapeutics Market

Nonalcoholic Steatohepatitis (NASH) Therapeutics Market to Reach US$20.27 bn by 2025, Elafibranor Projected to Spur Growth According to a new market report published by Transparency Market Research “Nonalcoholic Steatohepatitis Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2025�, the nonalcoholic steatohepatitis (NASH) therapeutics market is anticipated to expand at a CAGR of 10.7% from 2015 to 2025 to reach US$20.27 bn by 2025.

There are a few key causes of a fatty liver, one of which is nonalcoholic fatty liver disease. It occurs when excessive alcohol consumption causes large deposits of fat in the liver. It is one of the most commonly linked diseases to alcoholism and also one of the most commonly found liver disorders in developed economies. Non-alcoholic fatty liver disease (NAFLD) is caused by reasons linked to metabolic issues and insulin resistance.

Obesity is another factor that can significantly increase the chances of contracting NAFLD. According to the National Health and Nutrition Examination Survey, the rate of NAFLD in the U.S. within 2011 and 2012 was nearly 30%. In cases where NAFLD was not detected in time and reached higher levels of complications, non-alcoholic

steatohepatitis (NASH) can occur. It is the most extreme form of non-alcoholic fatty liver disease and is a direct causative factor for liver cirrhosis.

Browse Full Research Report on Nonalcoholic Steatohepatitis Therapeutics Market: http://www.transparencymarketresearch.com/nonalcoholicsteatohepatitis-market.html NAFLD by itself can be treated successfully if detected in time.

NASH, on the other hand, needs special care. The global nonalcoholic steatohepatitis therapeutics market is expected to reach US$20.2 bn by the end of 2025. It is expanding at a CAGR of 10.70% between 2015 and 2025.

Elafibranor Propels Global NASH Market The major segments of the market by drug type include Saroglitazar, Aramchol, Elafibranor, Obeticholic acid, and potential drug candidates in phase III. Elafibranor is expected to lead the market in the near future by being the largest and fastest growing segment of the global non-alcoholic steatohepatitis therapeutics market. Elafibranor is currently the most advanced and most effective drug in this market and is expected to exhibit the highest CAGR of all the various drug types.

There are no treatments that are specifically used for nonalcoholic steatohepatitis. Apart from the various drugs used for the treatment of fatty liver, doctors often suggest the patient to start losing weight if they are overweight. Other suggestions given include completely avoiding alcohol, consuming a balanced diet, and increasing physical activity.

NASH and NAFLD Linked to Obesity Medical records are pointing to an increasing prevalence of NAFLD and NASH across the world. However, these issues are more common in developed economies such as North America.

This is due to the larger percentage of the obese population in the total population in developed regions than others.

The global non-alcoholic steatohepatitis therapeutics market is, therefore, developing at a higher rate in countries such as the U.S., owing to the higher demand for NASH and NAFLD treatment options. The healthcare industry in these regions is taking fatty liver complications a lot more seriously.

In the recent past, the number of obese adults and children in the U.S. have doubled and tripled, respectively. This is a major

issue, as obese patients who suffer from NFALD or NASH are also likely to suffer from high blood cholesterol and diabetes.

Apart from obesity, patients of glucose intolerance and dyslipidemia are also prone to suffer from NFALD and NASH. There is no clear link that points to the reason NFALD occurs, but it is currently suggested that insulin resistance has a major role to play in it. In spite of the severity of the disease, patients are largely asymptomatic until complications arise. Therefore, the best preventive measure against NFALD and NASH is to lead a healthy life and moderate alcohol consumption.

The key players in this market that are expected to play a major role in the market’s immediate future include Tobira Therapeutics, Inc., Conatus Pharmaceuticals, Immuron Ltd., Zydus Cadila, Gilead Sciences, Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., and Astazeneca Plc. Browse Full Press Release on Nonalcoholic Steatohepatitis Therapeutics Market: Press Release

About Us Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.

Contact Us Transparency Market Research State Tower, 90 State Street, Suite 700, Albany NY - 12207 United States USA - Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com